Direct oral anticoagulant reversal: how, when and issues faced

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Increasing prevalence of atrial fibrillation (AF) necessitates oral anticoagulation therapy.
• Non-vitamin K oral anticoagulants (NOACs) offer alternatives to warfarin, improving therapeutic options for AF patients.
• Despite improved safety profiles, major bleeding remains a significant clinical challenge with NOACs.

Purpose of the Study:

• To review the risk of major bleeding in patients prescribed NOACs.
• To discuss general and specific approaches for managing NOAC-associated bleeding.
• To highlight the role and availability of reversal agents for NOACs.

Main Methods:

• Review of current literature on NOACs and bleeding management.
• Analysis of bleeding risk factors and severity assessment.
• Evaluation of hemostatic strategies, including reversal agents.

Main Results:

• Short half-lives of NOACs allow for simpler management (discontinuation, compression, volume substitution) in most bleeding cases.
• Non-specific reversal agents (e.g., prothrombin complex concentrates) can achieve hemostasis for Factor Xa inhibitors in life-threatening situations.
• Idarucizumab is currently the only approved specific reversal agent for dabigatran.

Conclusions:

• Effective management of NOAC-associated bleeding is essential for patient safety.
• Specific reversal agents are critical for managing severe or urgent bleeding events.
• The development and approval of additional specific reversal agents (andexanet alfa, ciraparantag) are anticipated.